Medy-Tox Tests New Botulinum Toxin Formulation MBA-P01 for Glabellar Lines
A Phase 2 trial evaluates MBA-P01, a novel botulinum toxin A, for safety and optimal dosing in treating frown lines.
Summary
This Phase 2 clinical trial investigated MBA-P01, a new botulinum toxin type A formulation developed by Medy-Tox, for the treatment of glabellar frown lines — the vertical creases between the eyebrows. The study used a two-period design: a 16-week dose-ranging phase comparing multiple doses of MBA-P01 against placebo, followed by a 36-week open-label extension period bringing the total study duration to 52 weeks. The goal was to identify the most effective and safest dose before advancing to larger trials. Botulinum toxin injections are among the most widely used cosmetic procedures globally, and new formulations may offer advantages in onset, duration, or tolerability. Results from this completed trial have not been publicly published in full, limiting interpretation of outcomes.
Detailed Summary
Cosmetic neurotoxin treatments have become one of the most performed aesthetic procedures worldwide, with botulinum toxin type A injections for glabellar frown lines representing a cornerstone of facial rejuvenation. As the market matures, pharmaceutical developers continue to introduce new formulations aiming to optimize efficacy, duration of effect, and safety profiles. This Phase 2 trial represents Medy-Tox's effort to bring MBA-P01, their proprietary botulinum toxin A product, through rigorous clinical evaluation.
The study enrolled subjects with moderate to severe glabellar frown lines and employed a placebo-controlled, dose-ranging design during the first 16 weeks. This initial phase was critical for identifying the therapeutic window — the dose range where efficacy is maximized without disproportionate adverse effects. Participants then entered a 36-week open-label extension, allowing long-term safety and durability data to be collected over a full year.
Glabellar lines form due to repeated contraction of the corrugator supercilii and procerus muscles. Botulinum toxin A works by blocking acetylcholine release at the neuromuscular junction, temporarily paralyzing these muscles and smoothing overlying skin. The primary endpoints in such trials typically include investigator and subject assessments of line severity at rest and during maximum frown.
The trial is now listed as completed on ClinicalTrials.gov, meaning data collection has concluded. However, peer-reviewed publication of results does not appear to be publicly available, which prevents detailed analysis of efficacy outcomes, responder rates, or adverse event profiles. This is a meaningful gap for clinicians and researchers evaluating this agent.
For longevity-focused audiences, aesthetic neurotoxin research intersects with broader questions about maintaining a youthful appearance and skin health across decades. Understanding which formulations offer the most favorable benefit-risk profile supports informed decision-making. Publication of full trial results would substantially advance the field's understanding of MBA-P01's place among established botulinum toxin products.
Key Findings
- MBA-P01 is a proprietary botulinum toxin A formulation evaluated in a Phase 2 placebo-controlled dose-ranging trial.
- The trial used a two-period design: 16-week dose-finding followed by a 36-week open-label extension for safety monitoring.
- The study targeted glabellar frown lines, one of the most common cosmetic treatment indications globally.
- Trial status is completed, but full efficacy and safety results have not been publicly published.
- Sponsor Medy-Tox is an established Korean biotech with prior botulinum toxin development experience.
Methodology
Phase 2, placebo-controlled, dose-ranging trial with a 16-week blinded period followed by a 36-week open-label extension totaling 52 weeks. Multiple doses of MBA-P01 were compared against placebo to establish the optimal therapeutic dose range. The study was sponsored by Medy-Tox and registered on ClinicalTrials.gov (NCT04143815).
Study Limitations
Full trial results have not been published in a peer-reviewed journal, making it impossible to assess efficacy outcomes, adverse event rates, or comparative performance against established products. This summary is based on the abstract and trial registry record only, with no access to primary data. The brief registry abstract provides minimal methodological detail, limiting evaluation of trial quality.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.